Company Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors.
Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management.
Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company.
The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Country | United States |
| Founded | 1995 |
| IPO Date | Apr 7, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Michael Exton |
Contact Details
Address: 2445 Technology Forest Boulevard, 11th Floor The Woodlands, Texas 77381 United States | |
| Phone | 281 863 3000 |
| Website | lexpharma.com |
Stock Details
| Ticker Symbol | LXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001062822 |
| CUSIP Number | 528872302 |
| ISIN Number | US5288723027 |
| Employer ID | 76-0474169 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael S. Exton Ph.D. | Chief Executive Officer and Director |
| Kristen L. Alexander | Vice President of Finance and Accounting |
| Brian T. Crum | Senior Vice President, General Counsel and Secretary |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation and Chemical Sciences |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President and Chief Medical Officer |
| Scott M. Coiante | Senior Vice President and Chief Financial Officer |
| Lisa M. DeFrancesco | Senior Vice President of Investor Relations and Corporate Communications |
| Dixon Terry | Vice President of Compliance |
| Carrie Siragusa | Vice President of Marketing |
| Desiree Gendron | Vice President of Sales and Training |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 28, 2025 | 8-K | Current Report |
| Jul 8, 2025 | SCHEDULE 13G/A | Filing |
| Jul 3, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |